Among the technologies in development to treat cancer, ex-vivo gene therapy has gained the most traction in the past 12 months. This follows regulatory approvals for therapies from Novartis and Gilead Sciences Inc where cells are extracted from a patient, treated in a laboratory and reinfused back into the patient.
